Nov 29,2017

A1C Improvement for People with Diabetes is Possible!

A study published in JMIR mHealth & uHealth found people with diabetes using the One Drop | Mobile app on their iPhone and Apple Watch reduce their hemoglobin A1c by an average 1.36%. Lowering A1c by an absolute 0.5% decreases cardiovascular disease by 10%. Each 1% A1c reduction is associated with a 37% decrease in the risk of microvascular complications and a 21% decrease in the risk of any diabetes-related complication or death.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 16,2017

Rimidi and Lilly Collaborate to Personalize Solutions for People Using Insulin

Rimidi, a digital health company that provides software and clinical analytics for chronic disease management, and Eli Lilly and Company (NYSE: LLY), a leader in diabetes care for more than 90 years, are coming together to develop provider-focused tools that will integrate personalized solutions for people who use insulin to manage their diabetes, the companies announced today. Rimidi will integrate its diabetes management software platform with Lilly’s integrated insulin management system in development.

COLLABORATION PARTNERSHIP

#connected device

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Dec 08,2017

Lilly begins Phase 1 study of automated insulin delivery system

Indianapolis-based pharmaceutical Eli Lilly and Company announced this week that the first Type 1 diabetes patient has been dosed in a feasibility study of the company’s investigational Automated Insulin Delivery (AID) system. The company’s hybrid closed-loop platform consists of an insulin pump with a dedicated controller for system inputs, a dosing algorithm, and a continuous glucose monitor (CGM).

CLINICAL STUDY

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Dec 12,2017

Ascensia Diabetes launches updated diabetes management app

Today Ascensia Diabetes Care UK launched the latest version of its Contour Diabetes app, a tool that helps people self-manage their diabetes, in the UK and Ireland. The app is designed to connect to the company’s Contour One Next blood glucose meter.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 18,2017

Bigfoot Biomedical's automated insulin delivery systems attract $37M in Series B funding

Milpitas, California-based diabetes management device maker Bigfoot Biomedical has raised $37 million in Series B funding in a round co-led by funds from Janus Henderson Investors and Quadrant Capital Advisors. Additional participants included Cormorant Asset Management, Senvest Capital Inc., Senvest Management LLC, Visionnaire Ventures, JDRF T1D Fund, and T1D Exchange.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Dec 20,2017

Biotech startup Nuritas raises €16 million in Series A funding

Nuritas, an Irish biotech startup, has raised €16 million in a Series A round led by US firm Cultivian Sandbox Ventures. Nuritas has built a medical platform that uses artificial intelligence to analyse peptides in food that can positively impact in conditions like pre-diabetes while reducing the cost and time needed to find them.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Dec 01,2017

Impact of Ramadan fasting on glucose levels in women with gestational diabetes mellitus treated with diet alone or diet plus metformin: a continuous glucose monitoring study

Women with gestational diabetes mellitus (GDM) are categorized as at high risk for adverse events during Ramadan fasting. However, this is largely based on clinical opinion. In this study, some light is shed on what happens to glucose levels during Ramadan fasting. The conclusion of the study is that CGM data indicates that Ramadan fasting in women with GDM treated with diet alone or with diet plus metformin was associated with lower mean glucose levels and higher rates of hypoglycemia when compared with non-fasting glucose levels. Women with GDM should be advised against fasting during Ramadan until further data is available.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 05,2017

Health2Sync lands $6 million in Series B funding for Japanese expansion

Diabetes management company Health2Sync is looking to expand its operation into Japan after raising $6 million in Series B investments led by Sompo Holdings, one of Japan’s largest insurance companies.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Dec 06,2017

Nemaura Announces Successful SugarBEAT® Interim Precision Study Results

Nemaura Medical Inc. (OTCQB: NMRD), a medical technology company focused on the development and commercialization of sugarBEAT®, a wireless adhesive skin-patch for adjunctive use by diabetics as a non-invasive and needle-free glucose monitoring system, today announced sugarBEAT® interim precision data results as part of its ongoing European clinical trial programme.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 07,2017

Tandem Diabetes Care Announces Retirement of CFO and Successor Appointment

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) today announced the retirement of its executive vice president and chief financial officer (CFO), John Cajigas, effective December 31, 2017. Leigh Vosseller, who is currently serving at Tandem's senior vice president of finance, will be promoted to CFO effective January 1, 2018.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES